GlassScriptPhysician profile
Jordan L Bailey
NPI 1225124936
$1,127.90
in general payments reported to CMS, 2019-2025
21 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $244 · 2021: $102 · 2022: $85.43 · 2023: $163 · 2024: $116 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.73 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $234.80 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $188.26 | 2019-2025 | Repatha, Otezla |
| Novo Nordisk INC | $107.33 | 2020-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.10 | 2019-2023 | Jardiance, Synjardy |
| Radius Health, INC. | $60.50 | 2019-2025 | Tymlos |
| Amarin Pharma, INC. | $53.23 | 2020-2021 | |
| Pfizer INC. | $40.19 | 2019-2023 | |
| Medtronic, INC. | $39.79 | 2024 | Corevalve Evolut R |
| Lilly USA, LLC | $35.80 | 2021-2025 | Zepbound, Mounjaro |
| Boston Scientific Corporation | $34.75 | 2022-2025 | General - Pain Management |
| Allergan, INC. | $33.93 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.30 | 2019 | |
| Esperion Therapeutics, INC. | $31.42 | 2020-2021 | |
| Lundbeck LLC | $26.74 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $25.42 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $24.99 | 2023 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $23.95 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $23.74 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $17.60 | 2025 | Voquezna |
| Genentech USA, INC. | $16.78 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.